

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **January 27, 2022**

BIMI International Medical Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-34890 (Commission File Number)	02-0563302 (IRS Employer Identification No.)
9th Floor, Building 2, Chongqing Corporation Avenue Yuzhong District, Chongqing, P. R. China (Address of principal executive offices)		116000 (Zip Code)

Registrant's telephone number, including area code: **(8604) 1182209211**

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$0.001 par value	BIMI	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 27, 2022, BIM I International Medical Inc. (the “Company”) entered into employment agreements with each of the Company’s COO, Mr. Xiaoping Wang, and Interim CFO, Ms. Baiqun Zhong, specifying the terms of their employment with the Company.

The agreement with Mr. Wang (the “COO Executive Employment Agreement”) is for a term of one (1) year, effective January 1, 2022. Under the COO Executive Employment Agreement, Mr. Wang’s compensation will consist of an annual salary of \$500,000 in cash and stock compensation of 500,000 shares of the Company’s common stock.

The agreement with Ms. Zhong (the “Interim CFO Executive Employment Agreement”) is for a term of one (1) year, effective May 21, 2021, taking into consideration that she served as the Interim CFO from May 21, 2021 until July 14, 2021 and assumed such role once again on September 27, 2021. Under the Interim CFO Executive Employment Agreement, Ms. Zhong’s compensation will consist of an annual salary of \$250,000 in cash.

The COO Executive Employment Agreement and the Interim CFO Executive Employment Agreement are filed herewith as Exhibit 10.1 and Exhibit 10.2.

Item 3.02 Unregistered Sale of Equity Securities.

The information required to be reported under this Item is incorporated by reference to Item 5.02 of this Current Report on Form 8-K.

The information under this Item 8.01 is deemed “furnished” and not “filed” under Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No	Document
10.1	Employment Agreement dated January 27, 2022
10.2	Employment Agreement dated January 27, 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 31, 2022

BIMI International Medical Inc.

By: /s/ Tiewei Song

Name: Tiewei Song

Title: Chief Executive Officer